Ensign Peak Advisors
BHVN

Ensign Peak Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Ensign Peak Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-102,726
Closed -$15.5M – 2348
2022
Q3 		$15.5M Hold
102,726
– – 0.04% 301
2022
Q2 		$15M Sell
102,726
-34,014
-25% -$4.34M 0.04% 311
2022
Q1 		$16.2M Buy
136,740
+14,327
+12% +$1.79M 0.03% 329
2021
Q4 		$16.9M Buy
122,413
+28,921
+31% +$3.68M 0.03% 354
2021
Q3 		$13M Buy
93,492
+14,031
+18% +$1.75M 0.03% 384
2021
Q2 		$7.71M Buy
79,461
+13,653
+21% +$1.11M 0.02% 502
2021
Q1 		$4.5M Buy
65,808
+29,522
+81% +$2.39M 0.01% 675
2020
Q4 		$3.11M Hold
36,286
– – 0.01% 815
2020
Q3 		$2.36M Sell
36,286
-28,256
-44% -$1.85M 0.01% 874
2020
Q2 		$4.72M Buy
64,542
+18,469
+40% +$983K 0.01% 621
2020
Q1 		$1.57M Buy
46,073
+20,647
+81% +$944K 0.01% 952
2019
Q4 		$1.38M Buy
+25,426
New +$1.26M ﹤0.01% 1212

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Ensign Peak Advisors's BHVN Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 102,726 shares — an estimated $15.5M sold.

Ensign Peak Advisors first reported a position in BHVN in Q4 2019 and held it in 12 quarters. The position peaked at $16.9M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 102,726 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $15.5M.
  • Ensign Peak Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2019 and held it in 12 quarters.
  • Ensign Peak Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $16.9M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.